Men´s Health devices

The urology device industry includes 8 key markets: urinary incontinence system, stone management device, BPH treatment equipment, urological endoscope, prostate cancer treatment appliance, urodynamic equipment, nephrostomy apparatus and erectile dysfunction device. Over 3 million procedures using a urology device were conducted in 2013.

Now Boston Scientific controls the Urological Device Market in the United States, after the purchase of American Medical Systems, with their substantial market share of benign prostate hyperplasia treatment equipments. C.R. Bard remains in second position and dominates the urinary incontinence appliance market. Olympus is expected to continue their lead in the urological endoscopes section. Other competitors in these markets are Coloplast, Karl Storz and also Covidien.

Players driving the European urological device market are Coloplast, a prominent player in the markets for nephrostomy devices, urinary incontinence slings, stone treatment devices and erectile dysfunction devices as well as Wellspect HealthCare, Teleflex, C. R. Bard and Olympus.

The current trends in the Urology device industry are market expansion, M&A acquisitions, an aging population, technological advances, new markets with a large population, lowering costs while raising quality, robotic surgery, reimbursement controls and regulatory issues.

The urology devices market is expected to reach over $3 billion in the USA and over $2 billion in Europe by 2020, driven by an aging population and an increasing number of procedures. This market consists of laser BPH devices, TURP tools, urinary catheters, brachytherapy, nephrostomy devices, urinary system incontinence slings, stone therapy devices, urological endoscopes as well as erectile dysfunction devices.

The andrology device industry includes 4 key markets: erectile dysfunction device, peyronie´s disease device, penile lengthening device and prostate post-surgery device.

Erectile Dysfunction (ED) is estimated to affect more than 150 million men worldwide and it is expected to double in 2030. Men affected by ED are 30 MM in the US & 20 MM in Europe. The U.S. market for ED therapies (drugs, VCD, PID) is valued at +$2.5 billion in 2016. Medicare paid +$172 MM for +473,00 VED from 2006 to 2011.

The Erectile Dysfunction causes are: diabetes, cardiovascular problems, prostate disease, medications, surgery, lifestyle choices (smoking, etc), depression/anxiety and low testosterone. ED drugs have hard side-effects, such as myocardial infraction (0.4-1.2%) and cardiac death (0.05-0.3%), and 30% of men with ED don´t respond well. Vacuum constriction device (VCD) for ED has high patient satisfaction, safety profile and 90% effectiveness. Penile implant device (PID) is a surgical therapy for ED; semi-rigid and inflatable types are available. The surgery will damage the cavernous bodies and should be last option.

Peyronie´s disease prevalence is 5% of adult men. A proven Peyronie traction therapy (PTT) with Collagenase and vitamin E will be the guideline in Peyronie´s disease as a simple ambulatory treatment, without the risky surgery which is last resort.

The 30% of men worry about the size of their penis, named small penis syndrome (SPS), and patients with micropenis (<2.7”). They can use a proven penile lengthening device based on penile traction therapy to get permanent results in a few months without any side effects.

In addition, urologists recommend the penis rehab after surgery after radical prostatectomy and Peyronie´s disease surgery with an extender based on penile traction therapy (PTT) to avoid penis shortening and with a vacuum erection device (VED) for tissue oxygenation.

The penis extenders market includes 3 key markets: penile traction therapy (PTT), penile lengthening device (PLD) and prostate post-surgery device.

Peyronie´s disease prevalence for adult men is 5%, and incidence in USA of 120,000 men every year. In UK there are +150,000 men with Peyronie condition, and NHS doesn´t pay the $5,000 of the implant. 47% of patients are motivated to seek PD treatment, 85% of men seek treatment within 3 months of diagnosis and the average time patients live with Peyronie´s ilness is 3.5 years.

The 67% of urologists are very knowledgeable about Peyronie´s disease, with a low satisfaction with some treatments. 1,000 urologists treat PD invasively and 7,000 urologists treat it non-invasively. Surgery is effective but has a very low acceptance due to adverse events. There is a Peyronie´s market opportunity for proven methods with no risk.

The Peyronie´s disease (PD) treatment market is based on surgery, enzimes and penile traction therapy.

The proven methods with low risks are penile traction device (PTT) and collagenase. The evidence indicates that colagenase gets a reduction of 28% of penile curvature and Penile traction device has a +50% of reduction. There is a Peyronie´s market opportunity for penile traction therapy with low risks and a lower price than collagenase injections.

American Urological Association is evaluating the good results of penile traction therapy in Peyronie´s disease in the study with Andropeyronie® which are: The mean curvature reduced from 33° at baseline to 15° at 6 months as well as 13° at 9 months with a mean reduction of 20° (P < 0.05) in the PTT group. VAS rating for pain reduced from 5.5 to 2.5 after 6 months (P < 0.05). EF and also erection hardness also improved considerably. The percentage of patients who were unable to achieve penetration reduced from 62% to 20% (P < 0.03). Penile traction therapy was connected with the disappearance of sonographic plaques of patients in 48%.

The penile lengthening device (PLD), known as penis extender, is a safe and effective proven method based on penile traction therapy for penile dysmorphophobia or small penis syndrome (SPS), known as the “locker room syndrome”, and for patients with micropenis (<2.7”).

Mondaini says the regular penis size is 3.5 inches (9 cm) flaccid, 4.5 inches (12.5 cm) stretched and 5.9 inches (15 cm) erect. There are effective methods in the market (surgery, penile traction therapy) and ineffective methods (massages, pills). ISAPS plastic surgeons society has stated that about +15,000 penile enlargement surgeries take place in the world per year, with a cost of $13,000/surgery, but the length gain is only 1 cm. The market of penis lengthening is a huge multi-million-pound global industry. There is a market opportunity for Penile traction therapy as a safe and proven method with a lower price and better results than a risky surgery.

NHS explains the good results of Penile Traction Therapy, which are in the study with Andropenis®: the mean gain in length after 6 months was considerable, satisfying the objectives of the result size, at 2.3 and also 1.7 cm for the flaccid and also stretched penis, respectively. The EF domain ratings enhanced substantially at the end of the research. The conclusions are: Penile extenders ought to be considered as a minimally invasive and also effective therapy choice to extend the penile shaft in people looking for therapy for a short penis.

Penile shortening after radical prostatectomy (RP) and Peyronie´s disease (PD) surgery can be devastating, and an unwelcome side effect of these operations, as it is researched by Dr. Levine´s study.

• Radical prostatectomy: 68% to 71% of patients after radical prostatectomy report a mean measured decrease of 1.1 to 4 cm.
• Peyronie’s Surgery: has been associated with penile shortening in 7.3% to 90% of patients. The amount of shortening also varies as much as 5 cm.

Penis rehab after radical prostatectomy and Peyronie´s disease is recommended, with a post-surgery device, based on penile traction therapy (PTT), to avoid penis shortening and with a vacuum erection device (VED) for tissue oxygenation.

The number of prostatectomy procedures in USA was 138,000 in 2010. A booming business alongside the sobering notion that more than 2 million men in the U.S. are now prostate cancer survivors. AMS calls the space the “erectile restoration market”. AMS believes the global market is worth $1.7 billion annually, with $500 million of that in the U.S. Penile implants made by both Coloplast and AMS cost about $12,000 each. There is a radical prostatectomy market opportunity for penile traction therapy to complement the success of the prostatectomy surgeries and to optimize the good results of the expensive penile implants for Erectile Dysfunction.

BAUS, the British urological surgeons association, explains the good results of Penile traction therapy with Andropenis® which are the prevention of penis shortening after surgeries. More recently, the use of penile traction (with the Andropenis® penile extender) for four to ten hours each day, over a period of three to six months, has been used.

The Therapies of Peyronie’s Disease Are an Unclear Business in 2019. Read it in PRNewswire.com

2019 New Treatment Guidelines for Peyronie’s Disease. Read it in PRNewswire.com

Andropeyronie study demonstrates successful Peyronie’s Disease management. Read it in Presswire.com

Penis Enlargement: a Non-Surgical and Professionally-Endorsed Reality. Read it in PRweb.com

Study Finds Penile Extender Can Increase Size by a Third, Released by Andromedical. Read it in PRweb.com